HCHarley H. L. Chan

Harley H. L. Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harley H. L. Chan has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does Freehand, Patient-specific Instrumentation or Surgical Navigation Perform Better for Allograft Reconstruction After Tumor Resection? A Preclinical Synthetic Bone Study

    by Harley H. L. Chan, Prakash Nayak, Ibrahim Alshaygy, Kenneth R. Gundle, Kim MD Tsoi, Michael J. Daly, Jonathan C. Md Irish, Peter C. Md Ferguson, Jay S. Md Wunder

    Background: Joint-sparing resection of periarticular bone tumors can be challenging because of complex geometry. Successful reconstruction of periarticular bone defects after tumor resection is often performed with structural allografts to allow for joint preservation. However, achieving a size-matched allograft to fill the defect can be challenging because allograft sizes vary, they do not always match a patient’s anatomy, and cutting the allograft to perfectly fit the defect is demanding. Questions/purposes: (1) Is there a difference in mental workload among the freehand, patient-specific instrumentation, and surgical navigation approaches? (2) Is there a difference in conformance (quantitative measure of deviation from the ideal bone graft), elapsed time during reconstruction, and qualitative assessment of goodness-of-fit of the allograft reconstruction among the approaches? Methods: Seven surgeons used three modalities in the same order (freehand, patient-specific instrumentation, and surgical navigation) to fashion synthetic bone to reconstruct a standardized bone defect. National Aeronautics and Space Administration (NASA) mental task load index questionnaires and procedure time were captured. Cone-beam CT images of the shaped allografts were used to measure conformance (quantitative measure of deviation from the ideal bone graft) to a computer-generated ideal bone graft model. Six additional (senior) surgeons blinded to modality scored the quality of fit of the allografts into the standardized tumor defect using a 10-point Likert scale. We measured conformance using the root-mean-square metric in mm and used ANOVA for multipaired comparisons (p < 0.05 was significant). Results: There was no difference in mental NASA total task load scores among the freehand, patient-specific instrumentation, and surgical navigation techniques. We found no difference in conformance root-mean-square values (mean ± SD) between surgical navigation (2 ± 0 mm; mean values have been rounded to whole numbers) and patient-specific instrumentation (2 ± 1 mm), but both showed a small improvement compared with the freehand approach (3 ± 1 mm). For freehand versus surgical navigation, the mean difference was 1 mm (95% confidence interval [CI] 0.5 to 1.1; p = 0.01). For freehand versus patient-specific instrumentation, the mean difference was 1 mm (95% CI -0.1 to 0.9; p = 0.02). For patient-specific instrumentation versus surgical navigation, the mean difference was 0 mm (95% CI -0.5 to 0.2; p = 0.82). In evaluating the goodness of fit of the shaped grafts, we found no clinically important difference between surgical navigation (median [IQR] 7 [6 to 8]) and patient-specific instrumentation (median 6 [5 to 7.8]), although both techniques had higher scores than the freehand technique did (median 3 [2 to 4]). For freehand versus surgical navigation, the difference of medians was 4 (p < 0.001). For freehand versus patient-specific instrumentation, the difference of medians was 3 (p < 0.001). For patient-specific instrumentation versus surgical navigation, the difference of medians was 1 (p = 0.03). The mean ± procedural times for freehand was 16 ± 10 minutes, patient-specific instrumentation was 14 ± 9 minutes, and surgical navigation techniques was 24 ± 8 minutes. We found no differences in procedure times across three shaping modalities (freehand versus patient-specific instrumentation: mean difference 2 minutes [95% CI 0 to 7]; p = 0.92; freehand versus surgical navigation: mean difference 8 minutes [95% CI 0 to 20]; p = 0.23; patient-specific instrumentation versus surgical navigation: mean difference 10 minutes [95% CI 1 to 19]; p = 0.12). Conclusion: Based on surgical simulation to reconstruct a standardized periarticular bone defect after tumor resection, we found a possible small advantage to surgical navigation over patient-specific instrumentation based on qualitative fit, but both techniques provided slightly better conformance of the shaped graft for fit into the standardized post-tumor resection bone defect than the freehand technique did. To determine whether these differences are clinically meaningful requires further study. The surgical navigation system presented here is a product of laboratory research development, and although not ready to be widely deployed for clinical practice, it is currently being used in a research operating room setting for patient care. This new technology is associated with a learning curve, capital costs, and potential risk. The reported preliminary results are based on a preclinical synthetic bone tumor study, which is not as realistic as actual surgical scenarios. Clinical Relevance: Surgical navigation systems are an emerging technology in orthopaedic and reconstruction surgery, and understanding their capabilities and limitations is paramount for clinical practice. Given our preliminary findings in a small cohort study with one scenario of standardized synthetic periarticular bone tumor defects, future investigations should include different surgical scenarios using allograft and cadaveric specimens in a more realistic surgical setting.


  • Open Access

    Figure S6 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Supplementary figure 6 and legend.

  • Open Access

    Data from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Photodynamic therapy (PDT) is a tissue ablation technique able to selectively target tumor cells by activating the cytotoxicity of photosensitizer dyes with light. PDT is nonsurgical and tissue sparing, two advantages for treatments in anatomically complex disease sites such as the oral cavity. We have previously developed PORPHYSOME (PS) nanoparticles assembled from chlorin photosensitizer–containing building blocks (∼94,000 photosensitizers per particle) and capable of potent PDT. In this study, we demonstrate the selective uptake and curative tumor ablation of PS-enabled PDT in three preclinical models of oral cavity squamous cell carcinoma (OCSCC): biologically relevant subcutaneous Cal-33 (cell line) and MOC22 (syngeneic) mouse models, and an anatomically relevant orthotopic VX-2 rabbit model. Tumors selectively uptake PS (10 mg/kg, i.v.) with 6-to 40-fold greater concentration versus muscle 24 hours post-injection. Single PS nanoparticle–mediated PDT (PS-PDT) treatment (100 J/cm2, 100 mW/cm2) of Cal-33 tumors yielded significant apoptosis in 65.7% of tumor cells. Survival studies following PS-PDT treatments demonstrated 90% (36/40) overall response rate across all three tumor models. Complete tumor response was achieved in 65% of Cal-33 and 91% of MOC22 tumor mouse models 14 days after PS-PDT, and partial responses obtained in 25% and 9% of Cal-33 and MOC22 tumors, respectively. In buccal VX-2 rabbit tumors, combined surface and interstitial PS-PDT (200 J total) yielded complete responses in only 60% of rabbits 6 weeks after a single treatment whereas three repeated weekly treatments with PS-PDT (200 J/week) achieved complete ablation in 100% of tumors. PS-PDT treatments were well tolerated by animals with no treatment-associated toxicities and excellent cosmetic outcomes.Significance:PS-PDT is a safe and repeatable treatment modality for OCSCC ablation. PS demonstrated tumor selective uptake and PS-PDT treatments achieved reproducible efficacy and effectiveness in multiple tumor models superior to other clinically tested photosensitizer drugs. Cosmetic and functional outcomes were excellent, and no clinically significant treatment-associated toxicities were detected. These results are enabling of window of opportunity trials for fluorescence-guided PS-PDT in patients with early-stage OCSCC scheduled for surgery.

  • Open Access

    Data from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Photodynamic therapy (PDT) is a tissue ablation technique able to selectively target tumor cells by activating the cytotoxicity of photosensitizer dyes with light. PDT is nonsurgical and tissue sparing, two advantages for treatments in anatomically complex disease sites such as the oral cavity. We have previously developed PORPHYSOME (PS) nanoparticles assembled from chlorin photosensitizer–containing building blocks (∼94,000 photosensitizers per particle) and capable of potent PDT. In this study, we demonstrate the selective uptake and curative tumor ablation of PS-enabled PDT in three preclinical models of oral cavity squamous cell carcinoma (OCSCC): biologically relevant subcutaneous Cal-33 (cell line) and MOC22 (syngeneic) mouse models, and an anatomically relevant orthotopic VX-2 rabbit model. Tumors selectively uptake PS (10 mg/kg, i.v.) with 6-to 40-fold greater concentration versus muscle 24 hours post-injection. Single PS nanoparticle–mediated PDT (PS-PDT) treatment (100 J/cm2, 100 mW/cm2) of Cal-33 tumors yielded significant apoptosis in 65.7% of tumor cells. Survival studies following PS-PDT treatments demonstrated 90% (36/40) overall response rate across all three tumor models. Complete tumor response was achieved in 65% of Cal-33 and 91% of MOC22 tumor mouse models 14 days after PS-PDT, and partial responses obtained in 25% and 9% of Cal-33 and MOC22 tumors, respectively. In buccal VX-2 rabbit tumors, combined surface and interstitial PS-PDT (200 J total) yielded complete responses in only 60% of rabbits 6 weeks after a single treatment whereas three repeated weekly treatments with PS-PDT (200 J/week) achieved complete ablation in 100% of tumors. PS-PDT treatments were well tolerated by animals with no treatment-associated toxicities and excellent cosmetic outcomes.Significance:PS-PDT is a safe and repeatable treatment modality for OCSCC ablation. PS demonstrated tumor selective uptake and PS-PDT treatments achieved reproducible efficacy and effectiveness in multiple tumor models superior to other clinically tested photosensitizer drugs. Cosmetic and functional outcomes were excellent, and no clinically significant treatment-associated toxicities were detected. These results are enabling of window of opportunity trials for fluorescence-guided PS-PDT in patients with early-stage OCSCC scheduled for surgery.

  • Open Access

    Supplementary Methods from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

  • Open Access

    Figure S9 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Supplementary figure 9 and legend.

  • Open Access

    FIGURE 2 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Photophysical and photochemical characterization of PS nanoparticles. A, Structure and composition of PS: PEGylated porphyrin-lipid conjugate-containing nanoparticles. B, Transmission electron microscopy of negatively stained PS nanoparticle morphology. Scale bar, 0.1 µm. C, Molar attenuation coefficient (ε) profile of intact and disassembled PS in aqueous media. Intact PS are suspended in 1x PBS and disassembled PS are treated with a non-ionic surfactant (Triton X-100). Note ε reported here on basis of mols of porphyrin-lipid conjugate. D, Fluorescence spectra of intact and disassembled PS nanoparticles in aqueous media at excitation wavelength 416 nm. Note the 100-fold increase in fluorescence intensity in the disassembled PS versus the intact PS at 675-nm wavelength. E, Singlet oxygen (1O2) generation of intact and disassembled PS nanoparticles in aqueous media with increasing light dose. Note the approximately 4-fold increase in 1O2 generation in the disassembled PS versus the intact PS using 671-nm excitation wavelength (50 mW). Mean ± SD. N = 5 samples/light dose. Additional material characterizations of PS described in Supplementary Fig. S1 and Supplementary Table S1.

  • Open Access

    Figure S1 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Supplementary figure 1 and legend.

  • Open Access

    FIGURE 3 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Pharmacokinetic profiles of PS nanoparticles in tumor-bearing mice and rabbit models of oral cavity cancer. Plasma concentration-time profiles of PS in Cal-33 and MOC22 mouse models (A) and VX-2 rabbit model (B). Units µg/mL. Additional pharmacokinetic analysis is detailed in Supplementary Table S2. Tissue concentrations of PS in Cal-33 and MOC22 mouse models (C) and VX-2 rabbit model (D) 24 hours post-injection. Units µg/g. Additional tissue distribution data are provided in Supplementary Tables S3–S5. Ratios of PS tissue concentration normalized to muscle concentration in Cal-33 and MOC22 mouse models (E) and VX-2 rabbit model (F) 24 hours post-injection. Unitless. Representative fluorescence images and ratios of PS ex vivo tissue fluorescence normalized to muscle fluorescence in Cal-33 and MOC22 mouse models (G), and VX-2 rabbit model (H) 24 hours postinjection. Unitless. Additional PS tissue selectivity data are provided in Supplementary Tables S6 and S7. For A, B, Mean ± SD. Table statistics: mean ± SE N = 5 mice/model. N = 6 rabbits. For C, D, E, and F, Tukey box-and-whisker plot with “+” denoting mean (mean value labeled above). N = 5 mice/tissue/model. N = 3 rabbits/tissue. For G and H, Bar plot with mean + SD (mean value labeled above). N = 5 mice/tissue/model. N = 3 rabbits/tissue. For G, Ex: 675 nm, Em: 720 nm, 1 second exposure time. For H, Ex: 675 nm, Em: 720 nm long pass. For mouse models: PS dose = 10 mg/kg, 400–500 MBq 64Cu/kg, i.v. For rabbit models: PS dose = 10 mg/kg, i.v.

  • Open Access

    FIGURE 2 from Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

    by Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, et al.

    Photophysical and photochemical characterization of PS nanoparticles. A, Structure and composition of PS: PEGylated porphyrin-lipid conjugate-containing nanoparticles. B, Transmission electron microscopy of negatively stained PS nanoparticle morphology. Scale bar, 0.1 µm. C, Molar attenuation coefficient (ε) profile of intact and disassembled PS in aqueous media. Intact PS are suspended in 1x PBS and disassembled PS are treated with a non-ionic surfactant (Triton X-100). Note ε reported here on basis of mols of porphyrin-lipid conjugate. D, Fluorescence spectra of intact and disassembled PS nanoparticles in aqueous media at excitation wavelength 416 nm. Note the 100-fold increase in fluorescence intensity in the disassembled PS versus the intact PS at 675-nm wavelength. E, Singlet oxygen (1O2) generation of intact and disassembled PS nanoparticles in aqueous media with increasing light dose. Note the approximately 4-fold increase in 1O2 generation in the disassembled PS versus the intact PS using 671-nm excitation wavelength (50 mW). Mean ± SD. N = 5 samples/light dose. Additional material characterizations of PS described in Supplementary Fig. S1 and Supplementary Table S1.